Semaglutide Side Effects

Nausea is the most common reason patients consider discontinuing semaglutide, but several strategies can significantly reduce its impact. Eat smaller, more frequent meals rather than large portions. Avoid fatty, fried, or heavily spiced foods during titration. Stay well-hydrated with small, frequent sips of water throughout the day.

Timing matters: some patients find that taking their injection in the evening reduces next-day nausea. If nausea is severe, your provider may slow the titration schedule, keeping you at a lower dose for 8 weeks instead of 4 before increasing. Over-the-counter remedies like ginger supplements or vitamin B6 may provide additional relief.

Supplement support specifically formulated for GLP-1 users can help manage GI symptoms during the adjustment period. Products targeting gut health, electrolyte balance, and digestive comfort can improve tolerability.

While rare, semaglutide carries risks of serious side effects that require immediate medical attention. Pancreatitis symptoms include severe, persistent abdominal pain that may radiate to the back, sometimes accompanied by vomiting. This occurs in less than 1% of patients but requires emergency evaluation.

Gallbladder disease (cholelithiasis) occurs in approximately 2-3% of patients on higher doses. Rapid weight loss increases gallstone risk regardless of the method. Symptoms include right upper quadrant pain, especially after fatty meals.

Acute kidney injury can occur secondary to dehydration from persistent vomiting or diarrhea. Monitor your hydration status and contact your provider if you cannot keep fluids down for more than 24 hours.

Semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies. The relevance to humans is unknown, and no causal link has been established in human populations. However, semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Symptoms to watch for include a lump or swelling in the neck, difficulty swallowing, hoarseness, or shortness of breath. Report any of these to your healthcare provider promptly.

For most patients, GI side effects peak during the first 2-4 weeks at each new dose level and gradually improve. By the time patients reach their maintenance dose and have been stable for 4-8 weeks, the majority report significant improvement or complete resolution of nausea and other GI symptoms.

Approximately 5-7% of patients in clinical trials discontinued due to GI adverse events. Patients who follow the recommended titration schedule and use management strategies have significantly better adherence rates than those who attempt to escalate doses too quickly.